Business context and reporting period
The supplied filing is Nuvilex, Inc.’s Form 10-Q, not a Pharmacyte Biotech, Inc. filing. It covers the quarter and six months ended October 31, 2013, in Nuvilex’s fiscal year. Nuvilex reported a shift toward biotechnology, including cancer and diabetes programs using its Cell-in-a-Box live-cell encapsulation technology.
Financial results and liquidity
| Metric | Three months ended October 31, 2013 | Six months ended October 31, 2013 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $448,570 | $1,849,261 |
| Operating loss | $448,570 | $1,849,261 |
| Net loss | $5,658,070 | $10,324,437 |
Six-month operating cash use was $366,769; investing cash use was $2,551,215, including $2.5 million for licenses; financing provided $3,115,275. Cash rose from $199,303 at April 30 to $396,594 at October 31. The company had $472,647 in current assets and $990,967 in current liabilities, a working-capital deficit of approximately $518,320. Total liabilities were $990,967, including $420,000 in loans payable. Total assets were $4,594,269 and stockholders’ equity was $3,603,302.
Material changes versus prior periods
- Revenue fell to zero from $6,287 in the three-month comparison and from $12,913 in the six-month comparison. Management said it discontinued Cinnergen because its manufacturing and marketing costs exceeded revenue.
- Six-month net loss increased from $893,333 to $10,324,437. The increase was largely driven by a $5,895,000 loss on conversion of preferred stock and a $3,973,795 loss on settlement of debt, alongside higher operating losses.
- Six-month compensation expense rose to $862,261 from $345,877, including $480,000 in director stock compensation. Operating cash use increased from $169,880 in the prior-year six-month period.
- In July 2013, Nuvilex completed the Bio Blue Bird acquisition and obtained a 14.5% interest in SG Austria. It also acquired exclusive worldwide diabetes-treatment licensing rights and made a $1 million payment; a further $1 million payment was due by April 30, 2014.
Outlook, risks, contingencies and unusual items
Management planned preparations for a Phase 2b pancreatic-cancer trial followed by a Phase 3 trial, subject to funding, clinical results and regulatory requirements. It also planned preclinical diabetes research. These are plans, not assurances of trial completion or approval.
The filing explicitly raises substantial going-concern doubt: Nuvilex had no established recurring revenue, an accumulated deficit of $51,770,544, and expected future losses. It said additional capital was necessary to fund operations and clinical development; inadequate financing could force the company to delay or abandon plans or cease operations. Management relied on equity financing and investor support. The period included substantial stock issuance and dilution, including 54 million common shares issued upon conversion of 8,500 Series E preferred shares. The preferred conversion and debt settlement generated large accounting losses.
At October 31, a $400,000 alleged licensing-fee obligation was reported as subsequently settled; a separate $20,000 note plus accrued interest was past due and under settlement negotiations. Subsequent events included settlements involving patent rights and share issuance, including 2 million shares to Brown University. Management reported no material pending legal proceedings at the filing date and no material change to previously disclosed risk factors. It concluded disclosure controls were effective.
Important facts for investors to verify
- Confirm the intended issuer: this filing is for Nuvilex, Inc., despite the request naming Pharmacyte Biotech, Inc.
- Verify available financing, near-term cash needs, and whether the additional diabetes-license payment was made.
- Check clinical-trial progress, manufacturing arrangements, and regulatory requirements for the planned programs.
- Review the preferred-stock conversion terms, resulting dilution, outstanding warrants, and subsequent share issuances.
- Confirm the status of the past-due note and the reported subsequent debt and legal settlements.